Ken Griffin Maxcyte, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Maxcyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 237,642 shares of MXCT stock, worth $301,805. This represents 0.0% of its overall portfolio holdings.
Number of Shares
237,642
Previous 8,700
2631.52%
Holding current value
$301,805
Previous $36,000
1700.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding MXCT
# of Institutions
120Shares Held
72MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY10MShares$12.7 Million1.17% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$10.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY7MShares$8.89 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X06.6MShares$8.38 Million1.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$7.11 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $129M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...